BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19442514)

  • 1. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
    Locke JA; Nelson CC; Adomat HH; Hendy SC; Gleave ME; Guns ES
    J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):126-36. PubMed ID: 19442514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
    Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
    Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
    Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
    Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
    Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
    Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
    Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low carbohydrate, high protein diet suppresses intratumoral androgen synthesis and slows castration-resistant prostate tumor growth in mice.
    Fokidis HB; Yieng Chin M; Ho VW; Adomat HH; Soma KK; Fazli L; Nip KM; Cox M; Krystal G; Zoubeidi A; Tomlinson Guns ES
    J Steroid Biochem Mol Biol; 2015 Jun; 150():35-45. PubMed ID: 25797030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
    Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
    Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
    Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
    PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
    Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
    Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
    Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
    Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid hormone synthetic pathways in prostate cancer.
    Mostaghel EA
    Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo steroid biosynthesis in human prostate cell lines and biopsies.
    Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
    Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.
    Yenki P; Bhasin S; Liu L; Nabavi N; Cheng CW; Tam KJ; Peacock JW; Adomat HH; Tombe T; Fazli L; Ivanova L; Dusek C; Khosravi S; Guns EST; Wang Y; Buttyan R; Gleave ME; Ong CJ
    Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37800655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.
    Cardoso HJ; Figueira MI; Vaz CV; Carvalho TMA; Brás LA; Madureira PA; Oliveira PJ; Sardão VA; Socorro S
    Cell Oncol (Dordr); 2021 Apr; 44(2):385-403. PubMed ID: 33464483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.